BR112013026241A2 - sistema e método para liberação multifásica de fatores de crescimento - Google Patents
sistema e método para liberação multifásica de fatores de crescimentoInfo
- Publication number
- BR112013026241A2 BR112013026241A2 BR112013026241A BR112013026241A BR112013026241A2 BR 112013026241 A2 BR112013026241 A2 BR 112013026241A2 BR 112013026241 A BR112013026241 A BR 112013026241A BR 112013026241 A BR112013026241 A BR 112013026241A BR 112013026241 A2 BR112013026241 A2 BR 112013026241A2
- Authority
- BR
- Brazil
- Prior art keywords
- growth factor
- multiphase
- release
- released
- period
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Composite Materials (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ceramic Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
Abstract
resumo patente de invenção: "sistema e método para liberação multifásica de fatores de crescimento". a presente invenção refere-se a um sistema para a liberação multifásica de pelo menos um fator de crescimento em um local de tratamento que compreende um veículo de distribuição para liberação de pelo menos um fator de crescimento em um perfil de liberação inicial e um carreador para liberação de pelo menos um fator de crescimento em um perfil de liberação sustentada. o perfil de liberação inicial libera pelo menos um fator de crescimento durante um período de horas a dias, em que o fator de crescimento é liberado em uma grande quantidade inicialmente, com o restante sendo liberado em quantidades progressivamente menores. o perfil de liberação sustentada libera pelo menos um fator de crescimento durante um período de dias a semanas, em que o fator de crescimento é liberado em uma quantidade geralmente constante durante tal período. o sistema da invenção é particularmente adequado para aplicações em bioimplantes. a invenção também compreende métodos e kits para a liberação multifásica de pelo menos um fator de crescimento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474049P | 2011-04-11 | 2011-04-11 | |
PCT/CA2012/050234 WO2012139223A1 (en) | 2011-04-11 | 2012-04-11 | System and method for multiphasic release of growth factors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013026241A2 true BR112013026241A2 (pt) | 2019-09-24 |
Family
ID=47008753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013026241A BR112013026241A2 (pt) | 2011-04-11 | 2012-04-11 | sistema e método para liberação multifásica de fatores de crescimento |
BR112014024968-7A BR112014024968B1 (pt) | 2011-04-11 | 2012-10-17 | Sistemas na forma de bioimplantes com mistura de particulado em gel de poloxâmero para liberação multifásica de fatores de crescimento |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014024968-7A BR112014024968B1 (pt) | 2011-04-11 | 2012-10-17 | Sistemas na forma de bioimplantes com mistura de particulado em gel de poloxâmero para liberação multifásica de fatores de crescimento |
Country Status (11)
Country | Link |
---|---|
US (5) | US9675670B2 (pt) |
EP (1) | EP2696852B1 (pt) |
JP (1) | JP6224579B2 (pt) |
CN (1) | CN103596553B (pt) |
AU (2) | AU2012243410B8 (pt) |
BR (2) | BR112013026241A2 (pt) |
CA (1) | CA2833023C (pt) |
DK (1) | DK2836195T3 (pt) |
RU (2) | RU2017134806A (pt) |
WO (1) | WO2012139223A1 (pt) |
ZA (1) | ZA201307453B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015016264A2 (pt) * | 2013-03-14 | 2017-07-11 | Genzyme Corp | composições de crescimento ósseo termo-sensível |
US10265437B2 (en) | 2014-03-14 | 2019-04-23 | The Research Foundation For The State University Of New York | Neurogenic regulation of bone growth and bone degradation |
CN104894069B (zh) * | 2015-05-07 | 2019-07-12 | 中国人民解放军第四军医大学 | 一种光控胰岛素节律性分泌的组织工程装置 |
CN107412859B (zh) * | 2017-04-26 | 2020-07-14 | 温州医科大学附属口腔医院 | 一种双基因时序性缓释的组织工程支架材料的制备方法 |
RU2665155C1 (ru) * | 2018-01-10 | 2018-08-28 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации | Способ доставки биологически активных веществ в скаффолд |
CN109568670B (zh) * | 2018-10-24 | 2021-05-07 | 温州医科大学 | 一种子宫内膜损伤修复的水凝胶及其制备方法 |
SG11202106161PA (en) | 2018-12-25 | 2021-07-29 | Orthorebirth Co Ltd | A bone regeneration material having a cotton-wool like structure formed of a plurality of electrospun fibers |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761471A (en) | 1980-08-04 | 1988-08-02 | The Regents Of The University Of California | Bone morphogenetic protein composition |
US4789732A (en) | 1980-08-04 | 1988-12-06 | Regents Of The University Of California | Bone morphogenetic protein composition |
US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
EP0612348B1 (en) | 1991-11-04 | 2003-04-23 | Genetics Institute, LLC | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
ATE239514T1 (de) * | 1997-02-07 | 2003-05-15 | Stryker Corp | Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung |
CA2360938C (en) | 1999-02-02 | 2008-01-08 | Warren Oliver Haggard | Controlled release composite |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
US6589549B2 (en) * | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US20070190102A1 (en) | 2000-06-30 | 2007-08-16 | Ping Luo | Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment |
US6503109B1 (en) | 2000-07-19 | 2003-01-07 | Marshall D. Duffield | Swivel drive assembly |
US20080233165A1 (en) | 2000-08-07 | 2008-09-25 | Biolok International, Inc. | Time release calcium sulfate and growth factor matrix for bone augmentation |
US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US7671012B2 (en) * | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
CN1267590C (zh) * | 2004-06-11 | 2006-08-02 | 清华大学 | 一种用于组织修复的生长因子缓释体系的制备方法 |
US7325262B2 (en) | 2005-03-02 | 2008-02-05 | Standard Textile Co., Inc. | Bedding hem with associated interlining |
EP1893174A2 (en) | 2005-05-10 | 2008-03-05 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
US20060257492A1 (en) * | 2005-05-13 | 2006-11-16 | Depuy Products, Inc. | Suspension of calcium phosphate particulates for local delivery of therapeutic agents |
CN1733311A (zh) * | 2005-08-18 | 2006-02-15 | 同济大学 | 一种包裹药物或生长因子的纳米纤维的制备方法 |
US20070248675A1 (en) | 2005-09-08 | 2007-10-25 | Gwangju Institute Of Science And Technology | Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof |
US20070255422A1 (en) | 2006-04-25 | 2007-11-01 | Mei Wei | Calcium phosphate polymer composite and method |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
AU2009200540A1 (en) * | 2008-07-03 | 2010-01-21 | Induce Biologics Inc. | Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
US20110208305A1 (en) | 2008-08-05 | 2011-08-25 | University Of Miami | Composite bone grafts, particulate bone-calcium sulfate constructs, and methods of treating joint injuries |
US20110027331A1 (en) * | 2009-07-29 | 2011-02-03 | Warsaw Orthopedic, Inc. | An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation |
-
2012
- 2012-04-11 BR BR112013026241A patent/BR112013026241A2/pt not_active IP Right Cessation
- 2012-04-11 WO PCT/CA2012/050234 patent/WO2012139223A1/en active Application Filing
- 2012-04-11 CA CA2833023A patent/CA2833023C/en active Active
- 2012-04-11 JP JP2014504131A patent/JP6224579B2/ja active Active
- 2012-04-11 CN CN201280017716.1A patent/CN103596553B/zh active Active
- 2012-04-11 AU AU2012243410A patent/AU2012243410B8/en active Active
- 2012-04-11 RU RU2017134806A patent/RU2017134806A/ru not_active Application Discontinuation
- 2012-04-11 EP EP12771478.0A patent/EP2696852B1/en active Active
- 2012-04-11 RU RU2013150080A patent/RU2633057C2/ru not_active IP Right Cessation
- 2012-04-11 US US14/111,518 patent/US9675670B2/en active Active
- 2012-10-17 DK DK12874355.6T patent/DK2836195T3/da active
- 2012-10-17 BR BR112014024968-7A patent/BR112014024968B1/pt active IP Right Grant
-
2013
- 2013-10-07 ZA ZA201307453A patent/ZA201307453B/en unknown
-
2014
- 2014-10-08 US US14/509,840 patent/US9724389B2/en active Active
-
2017
- 2017-02-03 AU AU2017200773A patent/AU2017200773A1/en not_active Abandoned
- 2017-06-07 US US15/616,563 patent/US20170266259A1/en not_active Abandoned
- 2017-08-04 US US15/669,425 patent/US20170340707A1/en not_active Abandoned
-
2018
- 2018-12-04 US US16/209,510 patent/US20190117734A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2833023A1 (en) | 2012-10-18 |
AU2012243410B2 (en) | 2016-11-03 |
US20170266259A1 (en) | 2017-09-21 |
CN103596553B (zh) | 2019-01-08 |
RU2633057C2 (ru) | 2017-10-11 |
AU2012243410B8 (en) | 2016-11-17 |
ZA201307453B (en) | 2019-11-27 |
JP6224579B2 (ja) | 2017-11-01 |
DK2836195T3 (da) | 2021-05-25 |
RU2013150080A (ru) | 2015-05-20 |
WO2012139223A1 (en) | 2012-10-18 |
EP2696852B1 (en) | 2018-06-06 |
AU2012243410A8 (en) | 2016-11-17 |
AU2017200773A1 (en) | 2017-03-02 |
US9724389B2 (en) | 2017-08-08 |
AU2012243410A1 (en) | 2013-05-09 |
US20150196620A1 (en) | 2015-07-16 |
US9675670B2 (en) | 2017-06-13 |
EP2696852A4 (en) | 2014-09-24 |
EP2696852A1 (en) | 2014-02-19 |
BR112014024968B1 (pt) | 2022-11-29 |
US20170340707A1 (en) | 2017-11-30 |
US20190117734A1 (en) | 2019-04-25 |
JP2014510763A (ja) | 2014-05-01 |
BR112014024968A2 (pt) | 2017-07-11 |
CA2833023C (en) | 2020-07-21 |
US20140100161A1 (en) | 2014-04-10 |
CN103596553A (zh) | 2014-02-19 |
RU2017134806A (ru) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013026241A2 (pt) | sistema e método para liberação multifásica de fatores de crescimento | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CR20130524A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
CO6612271A2 (es) | Anticuerpos anti-cd40 | |
BR112013010078A2 (pt) | sistema de prevenção de ferida de pressão e método para evitar o desenvolvimento de feridas de pressão de um indivíduo | |
BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
CL2016001362A1 (es) | Composiciones y métodos para reducir eventos adversos cardiovasculares graves | |
BR112015029462A2 (pt) | Inibidores de quinase | |
CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
BR112015027477A2 (pt) | método para tratamento de um transtorno de deglutição | |
CL2013001129A1 (es) | Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer. | |
MX2015008021A (es) | Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. | |
BR112012010237A2 (pt) | sistema de revestimento de um componente, emprego do mesmo e marcação de estradas | |
CL2014000050A1 (es) | Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson. | |
MX2013013891A (es) | Sistema y metodo de tratamiento de agua anti-incrustaciones. | |
CY1123202T1 (el) | Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης | |
CO6571879A2 (es) | Composición de control de fitoenfermedades y su uso | |
CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. | |
IN2014DN08829A (pt) | ||
PA8798401A1 (es) | Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida | |
MY160777A (en) | Process for producing a polymeric film with a cured polysiloxane coating | |
BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |